<DOC>
	<DOCNO>NCT02592369</DOCNO>
	<brief_summary>Prospective , single arm , multi-center , observational , post market study document clinical device performance outcome Evolut R system use routine hospital practice large patient cohort treatment symptomatic native aortic valve stenosis stenosed , insufficient , combine surgical bioprosthetic valve failure necessitate valve replacement .</brief_summary>
	<brief_title>CoreValve™ Evolut R™ FORWARD Study</brief_title>
	<detailed_description>The study objective document clinical device performance outcome Evolut R system use routine hospital practice large patient cohort treatment symptomatic native aortic valve stenosis stenosed , insufficient , combine surgical bioprosthetic valve failure necessitate valve replacement . Prospective , single arm , multi-center , observational , post market study . In Australia Canada prospective , single arm , multi-center pre-market study . Up 60 center worldwide . Geographies may include Europe , Australia , Middle East Africa , Latin America Canada . Approximately 1000 implanted subject , consent follow-up three year . For subject , data collect preoperatively , intra-operatively , hospital discharge , 30 day , 1 , 2 3 year .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Symptomatic native aortic valve stenosis stenosed , insufficient , combine surgical bioprosthetic valve failure necessitate valve replacement Acceptable candidate elective treatment Evolut R System conformity local regulatory medico economic context Age ≥80 year OR consider high great risk surgical aortic valve replacement ( AVR ) high risk define : Society Thoracic Surgeons ( STS ) predict risk mortality ≥8 % OR Documented heart team agreement risk AVR due frailty comorbidities . Geographically stable willing return implant site followup visit Of legal age provide inform consent ( patient Informed Consent Data Release Form ) country enroll trial The patient inform nature study , able willing provide consent without assistance legal representative consent participate , authorize collection release his/her medical information signing Patient Informed Consent Data Release Form . Known hypersensitivity contraindication aspirin , heparin ( HIT/HITTS ) bivalirudin , ticlopidine , clopidogrel , Nitinol ( Titanium Nickel ) , sensitivity contrast medium , adequately premedicated Preexisting mechanical heart valve aortic position Ongoing sepsis , include active endocarditis Anatomically suitable Evolut R system Estimated life expectancy le 1 year Participating another trial may influence outcome trial Need emergency surgery reason</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>